Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
See the Cosentyx dosing schedule and summary of product characteristics.
PsO dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
The recommended dose for PsO is 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.1
Supporting your Cosentyx patients virtually
We have now digitised our patient packs, leaflets, dosing charts and more. Make sure you can continue to support your Cosentyx patients virtually by exploring our patient resources.
More product information
Summary of product characteristics for Cosentyx
This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; PsO, plaque psoriasis; SC, subcutaneous.
Reference
- Cosentyx Summary of Product Characteristics.
